PSN Member Profile

Dr. Jeffery Schlachter, D.O., A.C.O.I. – Board Certified Gastroenterology provider in Overland Park, Kansas.

Dr. Jeffery Schlachter

Member Biography

Dr. Schlacter is a native of New York and a graduate of Brooklyn College. He earned his medical degree from the Kansas City University of Medicine & Biosciences. He then completed residency in Internal Medicine in Columbus, Ohio followed by a fellowship in Gastroenterology at Barnes Hospital, Washington University School of Medicine in St. Louis, Missouri. He is Board Certified in Gastroenterology and Internal Medicine.

  • Certifications
  • Education
  • Awards & Honors
Internal Medicine American Board of Internal Medicine 1982 Gastroenterology American Osteopathic Board of Internal Medicine 1983

Brooklyn College
Brooklyn, NY
Degree: BS
1971

Kansas City College of Osteopathic Medicine
Kansas City, MO Degree: D.O.
1976

Postgraduate
Internship
Doctors’ Hospital of Columbus Ohio
Columbus, OH
1976-1977

Residency
Doctors’ Hospital of Columbus Ohio
Columbus, OH
1977-1979

Fellowship
Washington University School of Medicine
Barnes Hospital
Digestive Disease Center
St. Louis, MO
1979-1981

  • Quality Assurance Committee - Saint Luke’s East Surgicenter
  • Curriculum Committee - University of Health Sciences - 1981-1998
  • Chairman, Department of Internal Medicine - Saint Luke’s East Hospital - 2008

Professional Organizations

  • American Osteopathic Association
  • Jackson Country Osteopathic Association
  • American College of Osteopathic Internists
  • Kansas City Southwest Clinical Society
  • Florida Osteopathic Medical Association
  • Alumni Association-University of Health Sciences
  • College of Osteopathic Medicine

Publications & Presentations

  1. Aluminum complex in duodenal ulcer; once versus twice daily dosing.
  2. A double blind, multi-center, placebo-controlled evaluation of the safety and effectiveness of aluminum complex tablets (1 gram) in patients with endoscopically documented duodenal ulcers.
  3. Assessment of the healing effects of H2 blocker and NSAID induced gastro-duodenal mucosal damage.
  4. A comparison of H2 blocker 150 mg, qid, H2 blocker 200 mg qid and placebo in the treatment of erosive esophagitis.
  5. A dose-ranging study to compare PGEI 50 mcg, 100 mcg and 200 mcg tid in preventing gastro-duodenal mucosal lesions induced by NSAID 50 mg tid in patients with osteoarthritis and rheumatoid arthritis.
  6. Protocol to identify and to treat clinically significant upper GI lesions induced by NSAIDS and subsequently to evaluate in a double blind placebo controlled, parallel group study, the effect of PGEI, when co-administered with NSAIDS two or three times daily, in preventing gastro-duodenal lesions in patients with rheumatoid or osteoarthritis.
  7. Double blind comparative study of the efficacy and safety of PGEI and H2 blocker in the prevention of NSAID induced gastric ulcers and upper GI symptoms.
  8. Double blind placebo controlled study of the efficacy of PGEI in the healing of NSAID induced gastric ulcers.
  9. A multi-clinic, double blind, placebo controlled study of prophylactic PGEI therapy for prevention of recurrence of duodenal ulcers.
  10. Comparison study of the efficacy and upper gastrointestinal safety of a fixed combination of PGEI/NSAID versus NSAID alone in treating the signs and symptoms of rheumatoid arthritis.
  11. Comparison study of the efficacy and upper gastrointestinal safety of a fixed combination of PGEI/NSAID versus NSAID alone in treating the signs and symptoms of osteoarthritis.
  12. Comparison study of H2 blocker qid and placebo in the maintenance of healed erosive esophagitis.
  13. Double blind, dose ranging study to evaluate the effects of doses as needed up to twice daily of H2 blocker or antacid as compared to placebo in the treatment of intermittent heartburn.
  14. Comparison study of an H2 blocker 300 mg hs, H2 blocker 300 mg bid, H2 blocker 300 mg qid in the treatment of duodenal ulcer disease.
  15. Comparison study of an H2 blocker 300 mg versus placebo administered at bedtime for the treatment of benign gastric ulcer.
  16. Comparison of the efficacy and upper gastrointestinal safety of the three doses of an anti-ulcer agent and placebo, co-administered with an NSAID in patients with rheumatoid arthritis.
  17. Double blind, placebo controlled, comparative study of the efficacy and safety of three dosage regimens of a prostaglandin inhibitor in the prevention of NSAID induced gastric ulcers.
  18. A multi-center, randomized, double blind, placebo controlled evaluation of healing and relapse rates following oral GR122311X compared with GR88502X. H2 blocker and placebo in patient with benign gastric ulcer.
  19. A multi-center, randomized, double blind, placebo controlled evaluation of healing and relapse rates following oral GR122311X compared with GR88502X and placebo in patients with benign duodenal ulcer.
  20. A double blind, placebo controlled comparison of an H2 blocker qid and bid in the treatment of erosive esophagitis.

Dr. Jeffery Schlachter

Gastroenterologist

Facilities Served

Holton Community Hospital

Conditions Treated

  • Acid Reflux Disease (Gastroesophageal Reflux / GERD)
  • Celiac Disease
  • Hemorrhoids
  • Irritable Bowel Syndrome (IBS)
  • Hepatitis C
  • Acid Reflux Disease (GERD)
  • Ulcerative Colitis
  • Abdominal Pain
  • Constipation

Procedures Performed

  • Colonoscopy

Become A PSN Member Today!

Complete the following form to learn more about how we can help you find the perfect opportunity!

Name*
Zip Code*
This field is for validation purposes and should be left unchanged.